GIVAX
Early-stage biotechnology company developing oral, replicating viral-vector vaccines using engineered rotavirus genomes to generate mucosal immunity against gastrointestinal pathogens, with lead programs targeting rotavirus and norovirus for pediatric and adult use.
Industries
Nr. of Employees
small (1-50)
Products
Dual rotavirus/norovirus pediatric vaccine candidate
Combination oral vaccine candidate designed to provide pediatric protection against rotavirus and norovirus using an engineered rotavirus replicating vector.
Norovirus vaccine candidate for adults
Oral vaccine candidate using an engineered rotavirus vector intended to induce protection against norovirus in adult populations.
Dual rotavirus/norovirus pediatric vaccine candidate
Combination oral vaccine candidate designed to provide pediatric protection against rotavirus and norovirus using an engineered rotavirus replicating vector.
Norovirus vaccine candidate for adults
Oral vaccine candidate using an engineered rotavirus vector intended to induce protection against norovirus in adult populations.
Services
Establish strategic partnerships with academic institutions, investors and biopharma to support R&D, funding and program advancement.
Establish strategic partnerships with academic institutions, investors and biopharma to support R&D, funding and program advancement.
Expertise Areas
- Viral vector vaccine development
- Mucosal immunology and oral vaccine design
- Preclinical vaccine development and candidate selection
- Viral genome engineering
Key Technologies
- Replicating viral vectors (rotavirus-based)
- Viral genome manipulation and engineering
- Oral mucosal vaccine delivery
- Modular antigen design
News & Updates
Company selected to participate in the 2025 Boston Biotech Investor Day.
Mentioned in Science article discussing high circulation of certain viruses in the Northern Hemisphere.
Referenced in a New York Times opinion piece advocating the need for a norovirus vaccine in the United States.
Company presentation at the 2024 World Vaccine Congress.
Reported collaboration / funding to support vaccine development with Indiana University.
Company selected to participate in the 2025 Boston Biotech Investor Day.
Mentioned in Science article discussing high circulation of certain viruses in the Northern Hemisphere.
Referenced in a New York Times opinion piece advocating the need for a norovirus vaccine in the United States.
Company presentation at the 2024 World Vaccine Congress.
Reported collaboration / funding to support vaccine development with Indiana University.